Pep Gubau, Aizon CEO

Ex­clu­sive: With an eye to­ward ex­pan­sion, an AI com­pa­ny that sup­ports CD­MOs com­pletes $20M Se­ries C raise

An AI provider that caters to bio­phar­ma man­u­fac­tur­ers has closed a $20 mil­lion Se­ries C raise to ex­pand its op­er­a­tions and bring its third tech prod­uct to com­mer­cial­iza­tion. No­tably, the fund­ing round will in­crease its staff num­bers by more than 30% to over 100 em­ploy­ees.

Launched in 2014, San Fran­cis­co-based Aizon’s tech­nol­o­gy cap­tures da­ta from man­u­fac­tur­ing sites, which can then be used to im­prove drug pro­duc­tion. The com­pa­ny pro­vides its tech main­ly to CD­MOs and CMOs but has some phar­ma clients as well, CEO Pep Gubau told End­points News in an in­ter­view.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.